RTP Mobile Logo
Addressing Current Questions and Controversies: PARP Inhibition in the Management of Ovarian and Other Gynecologic Cancers
Released July 2016

Proceedings from the first of two independent satellite symposia during the Society of Gynecologic Oncology’s 2016 Annual Meeting on Women’s Cancer. Featuring perspectives from Drs Ursula A Matulonis, Kathleen Moore, Amit M Oza and Elizabeth M Swisher. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for gynecologic oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

    Gynecologic cancers are comprised of 5 primary cancers affecting the ovaries, uterine corpus (endometrial cancer), uterine cervix (cervical cancer), vulva and vagina. In 2016, it is estimated that approximately 105,890 new cases of gynecologic cancer will be documented in the United States and 30,890 individuals will succumb to these diseases. Of this diverse yet related group of tumors, ovarian cancer (OC) has continually been the most lethal, and for this reason significant resources have been invested over the past decade to try to identify genetic and other factors responsible for its proliferation. This emphasis proved fruitful with the introduction of PARP inhibitors into the investigational and clinical milieu.

    However, the recent availability of these agents mandates that treating physicians attain confidence and competence in identifying patients appropriate for treatment and requires that clinicians be aware of emerging data and available protocols so that they may effectively counsel their patients in this regard. These video proceedings from a CME symposium held during the Society of Gynecologic Oncology’s 2016 Annual Meeting on Women’s Cancer feature discussions with leading researchers with an expertise in gynecologic oncology regarding actual patient cases and related clinical research findings. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist gynecologic oncologists and other healthcare providers with the formulation of up-to-date clinical management strategies for various gynecologic cancers.

    • Use available guidelines and consensus statements to develop an evidence-based algorithm for conducting genetic screening for patients with gynecologic cancers.
    • Consider clinical investigator perspectives to assist healthcare professionals in the selection of a validated genetic testing platform or platforms for patients with gynecologic cancers, and use this information to guide treatment planning for these individuals and their immediate family members.
    • Understand the rationale for the investigation of PARP inhibition as monotherapy or in combination with other novel agents for patients with BRCA-mutant and BRCA wild-type advanced OC, and use this information to inform protocol and clinical treatment options for these individuals.
    • Appreciate the recent approval of olaparib for patients with highly refractory advanced OC, and safely integrate this agent into the clinical care of appropriate individuals.
    • Develop an understanding of the emerging efficacy data and toxicity profiles of investigational PARP inhibitors to effectively prioritize clinical trial opportunities for appropriate patients with gynecologic cancers.
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Ursula A Matulonis, MD
    Medical Director and Program Leader
    Gynecologic Oncology Program
    Associate Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, ImmunoGen Inc, Merck.

    Kathleen Moore, MD
    Jim and Christy Everest Endowed Chair in Cancer Research
    Director, Oklahoma TSET Phase I Program
    Stephenson Cancer Center
    Associate Professor
    Section of Gynecologic Oncology
    Director, Gynecologic Oncology Fellowship
    Department of Obstetrics and Gynecology
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    Advisory Committee: Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, ImmunoGen Inc, Pfizer Inc, Roche Laboratories Inc.

    Amit M Oza, MD
    Professor of Medicine, University of Toronto
    Interim Chief
    Division of Medical Oncology and Hematology
    Director, Clinical Cancer Research
    Co-Director, Bras Family Drug Development Program
    Princess Margaret Cancer Centre
    Toronto, Canada

    Advisory Committee and Clinical Trials: AstraZeneca Pharmaceuticals LP; Contracted Research: AstraZeneca Pharmaceuticals LP, Merck.

    Elizabeth M Swisher, MD
    Professor, Dept Ob/Gyn
    University of Washington
    Seattle, Washington

    Contracted Research: Abbott Laboratories, Clovis Oncology.

    CONSULTING GYNECOLOGIC ONCOLOGISTS — The following consulting gynecologic oncologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Ioannis Alagkiozidis, MD
    Chief of Gynecologic Oncology
    Bronx Lebanon Hospital
    Bronx, New York

    No relevant conflicts of interest to disclose.

    Barbara Buttin, MD
    Practice Leader, Gynecologic Oncology
    Northwestern Medicine Regional Medical Group
    Winfield, Illinois

    No relevant conflicts of interest to disclose.

    Joanie Mayer Hope, MD
    Medical Director, Providence Infusion Center
    Managing Partner, Alaska Women’s Cancer Care
    Director of Gynecologic Oncology
    Native Alaska Medical Center
    Anchorage, Alaska

    No relevant conflicts of interest to disclose.

    Lynn D Kowalski, MD
    Nevada Surgery and Cancer Care
    Medical Director, Las Vegas Institute for Robotic Surgery
    Vice Chief of Staff, Mountainview Hospital
    Las Vegas, Nevada

    Consulting Agreement: IntegraGen; Speakers Bureau: AstraZeneca Pharmaceuticals LP.

    Lyndsay J Willmott, MD
    Assistant Professor
    Division of Gynecologic Oncology
    Creighton University School of Medicine at Dignity Health St Joseph’s Hospital and Medical Center
    Phoenix, Arizona

    No relevant conflicts of interest to disclose.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology and Myriad Genetic Laboratories Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection

    A monitor set to 1280 x 1024 pixels or more

    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

    Adobe Flash Player 10.2 plug-in or later

    Adobe Acrobat Reader

    (Optional) Sound card and speakers for audio

    Last review date: July 2016
    Expiration date: July 2017

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Click below to select videos to play: